Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ferumoxytol

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

The future of market access through a communications lens

Communications will play a pivotal role in helping pharma to define the value agenda

EISAI

Eisai “appalled” at decision not to recommend Fycompa in Germany

Regulator says pharma company filed inadequate comparison data for its epilepsy drug

- PMLiVE

NICE recommends BMS-Pfizer’s Eliquis to prevent stroke

Joins Xarelto and Pradaxa anticoagulants as potential warfarin replacement

- PMLiVE

SMC approves Eliquis, restricts use of Rienso

Pfizer-BMS' anticoagulant backed but Takeda's drug given second-line recommendation

Sanofi’s Steve Oldfield to co-chair UK medicines access group

Takes over from UCB’s Matthew Speers in joint government/industry group

- PMLiVE

Access Partnership expands its senior team

Kevin Mayo joins as VP in the US and Pascal King as global director in London

- PMLiVE

NICE metrics flawed and should not be used, says EU study

ECHOUTCOME criticises used of quality adjusted life years in HTAs

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

Scotland launches £21m fund for rare conditions

Will pay for orphan medicines not recommended by the SMC

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links